clinical trial · NCT05701423
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
Biogen·—·terminated·n = 34
Multiple SclerosisNatalizumab
brief summary
The primary objective of this study is to better understand the pathophysiological background of end-of-dose symptoms (EOD) and thereby determine the percentage of participants who develop EOD under natalizumab (NTZ) as an example of interval therapy in MS and to detect specific changes through multimodal analyses, including radiological, blood and digital health measurements, that may be used as potential biomarkers in the future to map EOD.
started
Feb 8, 2023
primary completion
Jul 31, 2024
completion
Jul 31, 2024
last updated
Sep 19, 2024
detailed description
Participants will additionally be offered to record daily activity and sleep patterns as well as heart rate for the duration of the study.
official title
End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol